Robert B. Bazemore is CEO & President at Epizyme, Inc. (EPZM). They have made 7 open-market trades across 2 companies since 2019, most recently 2026-10-14.
CIK 0001620152
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $50K since 2021, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NUVB | BUY | 2021-03-30 | 2021-04-01 | $9.98 | $50K | +10.1% | +3.4% | -11.4% |
| EPZM | SELL | 2021-03-25 | 2021-03-29 | $7.85 | $162K | +10.0% | +9.2% | +23.8% |
| EPZM | SELL · 10b5-1 | 2021-02-04 | 2021-02-05 | $11.21 | $44K | -4.0% | -19.3% | -38.8% |
| EPZM | SELL | 2021-01-25 | 2021-01-27 | $11.41 | $138K | -2.4% | -19.3% | -31.3% |
| EPZM | SELL | 2020-06-26 | 2020-06-30 | $16.15 | $154K | -7.2% | -13.1% | -24.6% |
| EPZM | SELL | 2020-06-18 | 2020-06-22 | $22.00 | $220K | -13.0% | -19.4% | -29.6% |
| EPZM | SELL | 2020-03-25 | 2020-03-26 | $15.28 | $100K | -11.1% | +3.2% | -2.7% |
| EPZM | SELL | 2020-01-24 | 2020-01-27 | $21.82 | $396K | +1.6% | +1.0% | -18.4% |
| EPZM | SELL · 10b5-1 | 2019-06-13 | 2019-06-14 | $12.10 | $25K | +9.4% | +16.2% | +3.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.